The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens

Table 1 IC₅₀ of BEZ235 for growth inhibition in human lung cancer cells

Cell line	Histology	EGFR status	PTEN status	KRAS status	Response to gefitinib	IC₅₀ for BEZ235 (nM)
HBF^a	Normal	WT	Normal	WT	Resistance	> 10 μM
NBE^b	Normal	WT	Normal	WT	Resistance	> 10 μM
A549	Adenocarcinoma	WT	Normal	G12S	Resistance	31.57 ± 12.76
CL141	Adenocarcinoma	WT	Loss	WT	Resistance	43.30 ± 7.27
CL83	Adenocarcinoma	WT	Normal	WT	Resistance	19.94 ± 5.46
ZSY	Adenocarcinoma	WT	ND	ND	Resistance	6.86 ± 3.26
LIJ	Adenocarcinoma	WT	ND	ND	Resistance	193.40 ± 52.76
CL152	Squamous cell carcinoma	WT	Loss	WT	Resistance	45.49 ± 15.36
PC9	Adenocarcinoma	Exon 19 deletion	Normal	WT	Sensitive	19.81 ± 3.44
PC9IR	Adenocarcinoma	Exon 19 deletion	Normal	WT	Resistance	28.75 ± 0.98
CL25	Adenocarcinoma	Exon 19 deletion	Normal	WT	Partial sensitive	56.20 ± 5.66
H3255	Adenocarcinoma	L858R	Normal	WT	Sensitive	12.60 ± 2.53
H1975	Adenocarcinoma	L858R/T790 M	Normal	WT	Resistance	16.24 ± 3.63
CL97	Adenocarcinoma	G719A/T790 M	Normal	WT	Resistance	40.89 ± 27.42

ISSN: 1756-9966